Document

0001129928-23-000010.txt : 20230328 0001129928-23-000010.hdr.sgml : 20230328 20230328113414 ACCESSION NUMBER: 0001129928-23-000010 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20230328 FILED AS OF DATE: 20230328 DATE AS OF CHANGE: 20230328 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ONCOLYTICS BIOTECH INC CENTRAL INDEX KEY: 0001129928 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38512 FILM NUMBER: 23767274 BUSINESS ADDRESS: STREET 1: 804, 322 - 11 AVENUE SW CITY: CALGARY STATE: A0 ZIP: T2R 0C5 BUSINESS PHONE: 4036707380 MAIL ADDRESS: STREET 1: 804, 322 - 11 AVENUE SW CITY: CALGARY STATE: A0 ZIP: T2R 0C5 6-K 1 form6kcantorfutureofoncolo.htm 6-K Document

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

For the month of March 2023

Commission File Number 001-38512

Oncolytics Biotech Inc.

(Translation of registrant's name into English)

Suite 804, 322 11th Avenue SW

Calgary, Alberta, Canada T2R 0C5

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.


Form 20-F þ						Form 40-F o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's “home country”), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.


EXHIBIT NUMBER						DESCRIPTION

99.1						Press Release

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Oncolytics Biotech Inc.

(Registrant)

By:

/s/ Kirk Look

Date: March 28, 2023

Kirk Look
Chief Financial Officer

EX-99.1 2 cantorfutureofoncology.htm EX-99.1 Document

Oncolytics Biotech® to Participate in a Panel Presentation at Cantor Fitzgerald’s The Future of Oncology Virtual Symposium

SAN DIEGO, CA and CALGARY, AB, March 28, 2023 -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that Dr. Matt Coffey, President and Chief Executive Officer, will participate in the Novel Mechanisms with Important Readouts panel at Cantor Fitzgerald’s The Future of Oncology Virtual Symposium, which is taking place April 3-5, 2023 in a virtual format. Additional details on the panel presentation can be found below.

Date: Monday, April 3, 2023

Time: 11:00 a.m. ET

Panel Title: Novel Mechanisms with Important Readouts

A live webcast and archived replay of the panel presentation will be available to registered attendees of the symposium through the symposium website. Company management will also be participating in virtual one-on-one investor meetings at the symposium. To schedule a meeting, contact your Cantor Fitzgerald representative or email jpatton@oncolytics.ca.

About Oncolytics Biotech Inc.

Oncolytics is a biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers.

Pelareorep has demonstrated synergies with immune checkpoint inhibitors and may also be synergistic with other approved oncology treatments. Oncolytics is currently conducting and planning clinical trials evaluating pelareorep in combination with checkpoint inhibitors and targeted therapies in solid and hematological malignancies as it advances towards registration studies in metastatic breast cancer and pancreatic cancer. For further information, please visit: www.oncolyticsbiotech.com.


Company Contact Jon Patton Director of IR & Communication +1-858-886-7813 jpatton@oncolytics.ca			Investor Relations for Oncolytics Timothy McCarthy LifeSci Advisors +1-917-679-9282 tim@lifesciadvisors.com